The Dana-Farber Cancer Institute (DFCI)'s MatchMiner tool was developed to increase historically low clinical trial enrollment rates in adults with cancer. Roy Perlis, MD, MSc, Editor in Chief of JAMA+ AI, spoke with Kenneth Kehl, MD, MPH, about his recent study published in JAMA Network Open evaluating the AI tool's ability to fulfill its purpose through genome sequencing. Related Content: Clinical Trial Notifications Triggered by Artificial Intelligence–Detected Cancer Progression Considerations in Translating AI to Improve Care How AI Could Increase Clinical Trial Enrollment in Adults With Cancer